Fixed dose combination of perindopril with indapamide in primary prevention of cerebrovascular complications among patients with metabolic syndrome and arterial hypertension

Aim. To study 24-week Fixed dose combination of perindopril with indapamide (Noliprel®) therapy effects on parameters of 24-hour blood pressure monitoring (BPM), carbohydrate, lipid, and purine metabolism, tissue insulin sensitivity, and cerebral perfusion in patients with mild to moderate arterial...

Full description

Saved in:
Bibliographic Details
Main Authors: V. B. Mychka, K. M. Mamyrbaeva, V. P. Masenko, V. B. Sergienko, I. E. Chazova
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2006-02-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1109
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim. To study 24-week Fixed dose combination of perindopril with indapamide (Noliprel®) therapy effects on parameters of 24-hour blood pressure monitoring (BPM), carbohydrate, lipid, and purine metabolism, tissue insulin sensitivity, and cerebral perfusion in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-six patients with mild to moderate AH and MS participated in the study. All patients were administered Noliprel® or Noliprel® Forte (one tablet per day, in the morning). At baseline and 24 weeks later, all patients underwent 24-hour BPM, manual BP measurement, carbohydrate and lipid metabolism, peripheral tissue insulin sensitivity assessment, as well as cerebral scintigraphy, for cerebral perfusion assessment. Results. Noliprel® therapy was associated with target BP level achievement in 84% of the patients, and significant decrease in virtually all mean circadian BP profile parameters. Lipid metabolism parameters substantially improved, glycemia level decreased, initially reduced insulin sensitivity index increased. In all participants, bilateral cerebral perfusion, severely impaired at baseline, substantially improved. Conclusion. Noliprel® therapy in patients with AH and MS was associated with BP reduction, together with endothelial function improvement, peripheral tissue insulin sensitivity increase, and positive metabolic effects, that resulted in substantial improvement of cerebral perfusion.
ISSN:1728-8800
2619-0125